The estimated Net Worth of David Michael Clark is at least $3.74 million dollars as of 15 February 2024. Mr. Clark owns over 4,427 units of Amicus Therapeutics Inc stock worth over $2,858,793 and over the last 6 years he sold FOLD stock worth over $880,336. In addition, he makes $0 as Chief People Officer at Amicus Therapeutics Inc.
David has made over 7 trades of the Amicus Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,427 units of FOLD stock worth $61,978 on 15 February 2024.
The largest trade he's ever made was selling 21,507 units of Amicus Therapeutics Inc stock on 4 January 2023 worth over $255,288. On average, David trades about 3,059 units every 64 days since 2018. As of 15 February 2024 he still owns at least 253,664 units of Amicus Therapeutics Inc stock.
You can see the complete history of Mr. Clark stock trades at the bottom of the page.
David Clark serves as Chief People Officer of the Company. Mr. Clark was previously Vice President of Global Human Resources at Alibaba Group, headquartered in Hangzhou, China, from September 2016 to August 2018. Prior to that, David spent eight years at American Express, where he was Senior Vice President of Human Resources (HR) and Chief Learning Officer. While there, David was a senior HR Business Partner and led the transformation of learning, leadership development and performance management. Previously, David was a Commissioned Officer on the White House senior staff. As Deputy Assistant to the President of the United States, he led the recruitment and development of the 4,000 most senior leaders in the U.S. government. David received a B.S. in political science from Indiana State University. He is an Eagle Scout and serves on the National Executive Board of the Boy Scouts of America. David is also the Chairman of the Board of the Make-A-Wish Foundation of America.
David Clark is 45, he's been the Chief People Officer of Amicus Therapeutics Inc since 2018. There are 17 older and 2 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
David's mailing address filed with the SEC is 47 HULFISH STREET, , PRINCETON, NJ, 08542.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris et Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: